Increasing Expenditure On Life Science Research And Sterility Testing Market Development
Market growth influenced due to following factors-
- Rapid growth in the pharma and biotech industries.
- Increasing expenditure on life science research.
- Increasing number of drug launches.
Global market size-
According to the new market research report sterility testing market is expected to reach $941.0 Million by 2021, at a CAGR of 12.3%.
Leading Players -
Some of the major players operating in the pharmaceutical sterility testing market are Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (CHINA), and Thermo Fisher Scientific, Inc. (U.S.).
Top Segment -
On the basis of application, the pharmaceutical sterility testing market is segmented into pharmaceutical and biological manufacturing, medical devices manufacturing, and others applications. In 2016, the pharmaceutical and biological manufacturing segment is expected to account for the largest share primarily due to the rapid growth in the pharma and biotech industries.
On the basis of product, the pharmaceutical sterility testing market is segmented into kits and reagents, instruments, and services. The kits and reagents segment is expected to account for the largest share of the market. The large share of the kits and reagents segment can be attributed to the requirement of the repeat purchase of these products, coupled with the increasing preference for kit-based testing.
For More Details, Download PDF Brochure
Geographic Overview -
On the basis of region, the pharmaceutical sterility testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The Asian market will witness the highest growth during the forecast period, primarily due to the increasing expenditure on life science research in the region and growing trend of pharmaceutical outsourcing to Asian countries like India and China.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.